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Nowadays, the obligatory criteria that
enable to use pharmaceuticals in clinical prac
tice are the following: efficacy, safety and
quality. These parameters are determined by
the results of appropriate investigations, such
as: bioequivalence, pharmacological, toxico
logical and clinical trials and in vitro investi
gations. Efficacy and safety of pharmaceuti
cals are related to efficacy of their action on a
particular cellular target and to their ability
to maintain a high level of in vivo activity.
While developing new pharmaceuticals,
the researchers often don’t pay sufficient
attention to their targeted delivery. At the
same time it is clear that only a therapeutic
agent of high in vitro activity level, bioavail
ability and specificity can be effective. It
should be mentioned that present knowledge
about intracellular transport mechanisms and
molecular organization of cell surface allows
to develop new, more effective technologies of
targeted drug delivery. Use of these methods
is intended to raise the drugs action specifici
ty and to decrease in that way their toxicity
and the concentration of acting agents as well
[1, 2]. 
Effective intracellular delivery of pharma
ceuticals becomes particularly important in can
cer therapy [13]. The main reasons that essen
tially restrict efficacy of antitumor therapy are
low specificity as well as primary resistance of
tumor cells to chemotherapy agents and their
resistance acquired during the treatment. 
Two main approaches to selectivity
improving of pharmaceuticals based on direct
ed transport of acting agents to target cells by
means of liposomal forms and receptordepen
dent endocytosis (RDE) are discussed in the
article.
Liposomal drug formulations
Ability of liposomes to hold different sub
stances practically without restrictions on
their chemical nature and size of molecules
gives an unique opportunity to solve some
medical and biological problems. For example,
a lot of pharmaceuticals are characterized by
low therapeutic index because their medicinal
concentrations don’t differ a lot from toxic
concentration. Otherwise a medical product
can rapidly lose its activity under inactivating
agents action at a time of injection into an
organism. Inclusion of such medical products
in liposomes could greatly increase their the
rapeutic efficacy. On the one hand, medical
product contained in liposome is immuned
against the negative factors by liposome mem
brane. On the other hand the same membrane
doesn’t let a toxic product to exceed its maxi
mum permissible concentration in the organ
ism’s biological liquids. In this case liposome
acts as a depository whereof a medical product
is being released little by little in required
doses and during required time period [4–5].
In terms of biological compatibility, lipo
somes are the ideal carriers of pharmaceutials.
Their advantages are the following: natural
biocompatibility of liposome phospholipides,
that are the main component of biomembrane
lipid matrix; biodegradation to the products
that can be utilized to water and carbon dioxide;
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nontoxicity and nonantigenicity; good solubi
lization. Under definite conditions the cells
could absorb liposomes; their membrane could
conjugate to a cell membrane that leads to
intracellular delivery of their content [6].
It ought to be noted that liposomes are not
kept by such organs as heart, kidneys, brain
and nervous system cells. This phenomenon
allows to bring down significantly cardiotoxi
city, nephrotoxicity and neurotoxicity of the
important pharmaceuticals for anticancer
therapy. 
Disadvantage of liposomal forms is bad
pharmacokinetical characteristics caused by
instability of liposomes, their quick opsoniza
tion at intravenous introduction and further
absorption by a reticuloendothelial system
(RES). Thereat usually liposomal carriers
can’t be directed to those organs and tissues
where pathological process takes place [7].
It is known that pharmacokinetics of drugs
encapsulated in liposomes is determined by
coordination of two following factors: speed of
excretion of a liposomal agent from plasma
(purification) and stability of liposomes bond
ing with drugs in bloodstream. This process
depends on characteristics of a medical pro
duct and liposomal carrier, namely on lipo
somes size and their physical and chemical
characteristics, on permeability of individual
tissues, on the nature of bond between lipo
some and medical product [5, 8]. If liposome
surface is made as hydrophilic one under use
of covalent bonded polyethylene glycol (PEG),
liposomes could be protected against a reticu
loendothelial system. In its turn, this leads to
extension of halfcycle of a medical product
existence in bloodstream and to slow penetra
tion of the medical product into a tumor tissue
[9]. PEG coating also inhibits proteindepen
dent binding with the cells. Scheme of steric
stabilized liposome is following: proteins
couldn’t reach a liposome surface because of
osmotic overpressure in a membranous space;
flexible chains of immobilized polymers such
as PEG create overpressure.
Liposomes have great prospects for deliv
ering cytotoxic pharmaceuticals selectively
into tumor tissue. Thereby the researchers
should concentrate on a mechanism of selec
tive accumulation of liposomal forms of the
cytostatic agents in tumor tissue. Physiology
of solid tumors differs from that of the normal
tissues by a whole series of substantial aspects
[6, 10]. Tumor vesicles are often abnormal
misshapen capillaries with the permeable
walls and slowed blood flow in contrast with
regular and wellordered vascularization of
normal tissues. Tumor growth requires per
manent growth of the new vesicles. These dif
ferences could make problems physiologically
in cancer treatment. For example, hypoxia in
the solid tumors causes resistance to radio
therapy and to some antitumor agents.
However, these differences can be used for
selective cancer treatment. Permeable blood
vesicles can find application for use of lipo
somes with different structures as well as
steric stabilized liposomes. Penetration of par
ticles in majority of normal tissues is limited
by continuous endothelial covering of vesicles
[11]. Large particles and liposomes of more
than 250 nm in diameter don’t permeate prac
tically through the capillaries even if intercel
lular contacts and pores in endothelium are
sufficiently large. Close intercellular contacts
(26 nm) between endothelial cells and the
most normal tissues hinder extravasation even
for very small liposomal particles (up to 30 nm
in diameter). For example, tissues reach in
sinuses and capillaries (liver, spleen, marrow)
or pathological tissues are permeable for the
particles up to 100 nm in diameter. A lot of
primary and metastatic tumors have faltering
and high permeable system of vesicles that is
enough for exiting of small particles including
liposomal ones. Thus vesicles physiology
determines a heightened level of absorption in
liver, spleen and tumor tissues. This fact
explains the reasons of selective accumulation
of liposomal cytostatic agents in tumor.
Liposomes localization in tumor has been
proved to be a result of a heightened level of
penetration through the permeable tumor
vesicles in combination with lymphatic
drainage disorder [12, 13]. Specific structure
of the blood vesicles and small size of lipo
somes cause stable accumulation of a liposo
mal medical agent into a tumor. This effect
provides passive and directed delivery and
increases pharmaceutical therapeutic effec
tiveness. The morphological researches of
solid and ascitic tumors have shown that pre
sence of PEG liposomes is limited mostly by
tumor extracellular fluid; PEG liposomes
release gradually a medical agent in a tumor
area [9, 14].
It should be mentioned that liposomes
could be used not only for directed delivery of
the antitumor agents. Immune response
becomes stronger in case of liposomal vaccines
using. It happens because antigens associated
with liposomes get directly the antigenpre
senting cells. Liposomal hepatitis A vaccine
was one of the first to develop [15]. There were
incorporated proteins (influenza virus hemag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glutinin) that help liposome and cell mem
branes fusion as well as antigen (viral capsid)
into liposome. Nowadays these agents are
often referred to as «virosomes». Virosome
follows the natural way of viral particle and
consequently an antigen fragment in combina
tion with MHC II antigens are shown on the
antigenpresenting cell surface, i.e. in a form
wherein an antigen is recognized by Thelpers.
Liposomes enable constructing the polyvalent
vaccines, for example: several influenza
strains vaccine, hepatitis A, hepatitis B and
tetanus vaccines [16].
There are greate possibilities in liposomes
application in gene therapy [17, 18]. In genetic
material delivery, liposomes act as protectors
against nucleases and as compacting tool (po
sitively charged liposomes) and as endocytosis
initiator as well. It is known that the most
important phase of virosome processing is
fusion of its membrane and endosome mem
brane under action of hemagglutinin. In such
a case liposome content gets to cytosol, in
other words avoidance behavior of lysosomal
enzymes takes place. Exactly this way is con
sidered as primary one for liposomes carrying
genetic material. Liposomes are considered as
the most perspective carriers. Some composi
tions are found to be comparable by their
transfection efficacy with the adenoviral vec
tors [6].
In many cases especially for gene therapy, it
is important the address delivery into the cells
of a required type. Immunoglobulines that have
corresponding targets on the aim cells are often
chosen as «molecular addresses».
By means of liposomal different proteins
such as enzymes could be brought into an
organism with the purpose of enzymotherapy
and cytokines for the organism immune status
correction. Very substantial investigations
into creation of liposomes containing haemo
globin (haemosomes) with the purpose of
receiving artificial blood substitutes have
been carried out [5].
«Ideal» liposome model as a method of
directed delivery of a medical agent into a cell
is described in [6] (fig. 1). This liposome con
tains pharmaceutical substance, for example
DNA in case of gene therapy, in its inner
space. A molecular address and flexible poly
mer chains are immobilized on a liposome sur
face for decreasing absorption by RES cells.
Fusion proteins are incorporated into a mem
brane. Moreover, a membrane consists not
only of normal phospholipides making double
layer (usually it is phosphatidylcholine) but of
lipids that contribute to fusion with a cell
membrane (for example dioleinphosphati
dylethanolamin) as well.
Pegylated drugs
One way of increasing efficacy of protein
structure medical products (interferons, hor
mones, growth factors, cytokines etc.) is
chemical modification of their molecule
addressed not to their structure change but to
the native molecule transformation with poly
ethylenglycol (PEG). This chemical modifica
tion of peptidestructure pharmacological
agents is purposefully directed to their 
tolerance improvement, immunogenicity low
ering, halflife period prolongation [19].
PEG could be bonded with protein in several
positions, but some of them are premium, for
example, most often covalent connection with
protein (interferon α2b) takes place at the
lysine εamino group nitrogen atom or at the
histidine imidasole group. These bonds allow
to activate PEG hydroxyl groups and to build
molecule, that has covalent bonds on the tar
get places. Moreover, PEG straight covalent
bonds at lysine and arginine positions (car
boxyl ends) directly prevent modified mole
cules from trypsin breakdown [20].
One of the most important resources of
pegylated molecules is high hydrophilicity,
that controls new characteristics of modified
peptide. High content of hydrogen atoms even
in one PEG molecule enables it to bond with 2–3
water molecules. This effect leads to formation
Fig. 1. «Ideal» liposome model [1]:
1 — polymer for steric protection from RES cells; 2 —
«molecular address»; 3 — fusion proteins incorporated
into membrane; 4 — pharmaceutical substance; 5 —
double phospholipide layer; 6 — lipids that contribute
to fusion with cell membrane
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of a «water cloud» around a modified 
molecule and therefor its hydrodynamic
radius raises.
It is some kind of a water «shield» around
modified molecule that raises solubility and
bioavailability of a medical agent and protects
molecule from other proteins (neutralizing
antibodies, complement). Thus pegylated pep
tides are noticeably more protected from
opsonization, active phagocytosis and endocy
tosis of the cell structures. Monometoxy
ethylenglycol is used the most often for bond
ing peptide molecules. Its molecule has one
hydroxyl group that conjugates with protein;
other ends of PEG molecule contain nonreac
tive methyl groups [20, 21].
Changes in pharmacokinetic and pharma
codynamic characteristics of pegylated pep
tides depend on PEG molecule weight and on
specific bond places. For example, direct cor
relation between PEG molecule weight and
peptide halflife period was shown: increase of
this index ranges from 3–5 times (uricase,
streptokinase) to approximately 500 times
(superoxide dismutase) [22, 23]. One more
important factor, that affects the pharmacoki
netic and pharmacodynamics of PEGmodified
peptides is PEG chains structure: branched
PEG molecule forms deceleration of medical
agent active transport. It also causes prolon
gation of active circulation of medical agent.
Less immunogenicity of the modified medical
agents while saving their main pharmacologi
cal characteristics is also resulted from PEG
chains branched structure. Similar effects
could be obtained by other means — by peptide
conjugation with several PEG molecules having
linear chains structure [20–22]. In this case,
interleukin2 (IL2) is a wellknown example.
IL2 molecule is very small, that’s why it is
easily filtrated by kidneys and has a very short
halflife period. Junction of IL2 and PEG
with Мr > 20 kD doesn’t interfere practically
in protein pharmacodynamics but increase
in PEG molecular weight to 60–70 kD notice
ably slows down conjugate filtration and
increases its halflife period and bioavailabili
ty [24]. 
Modern technologies of pegylation of bio
logically potential peptide molecules resulted
in greatly extension field of their practical
application at present and in the future. Since
the advent of PEGmodified peptides forming
the number of pharmacodynamic and pharma
cokinetic effects has been allowed which were
impossible before now for the specific peptide.
Results of the clinical trials with pegylated
erythrocytes, α2b interferon, adenosine dea
menase, and tumor necrosis factor soluble
receptor are brilliant examples of this phe
nomenon [25–28].
Pegylated erythrocytes. The most actual
problem is blood erythrocytes transfusion to
the chronic patients, who receive transfusions
regularly. They are the patients who suffer
from sickle cell disease, thalassemia, and the
patients being treated with hemodialysis
because of chronic renal insufficiency. It is
clear that this group of the patients is mostly
inclined to external antigen aggression and to
a risk of alloimmunization forming [19].
Creation and clinical trials of PEGmodified
erythrocytes were performed to solve this
problem. Physicochemical structure of PEG,
together with its viscosity characteristics,
high molecule stability and hydrodynamic
parameters enabled to create highperfor
mance conjugate with erythrocytes. During
the experiment, the short linear PEG chains
made it possible to «screen» Rh factor and
other surface antigens, while the long chains
promoted blocking of erythrocytes adhesion
between each other and that of the vesicles
endothelium. Futhermore the long PEG chains
prevented erythrocytes from damage and their
deformation in a vascular bed. Branched PEG
chains with compact areactogenic zones
blocked external antigens connection and
their production effectiveness regarding to
erythrocytes injected from the outside. PEG
erythrocytes obtained in such a way showed
their high performance both on the animal
models and in the researches in humans.
Besides there were no side effects that usually
accompany hemotransfusions. In such a case
total hemodynamics was certainly improved,
oxygen transport cell function was prolonged
and indices of rheology parameters were sub
stantially improved. It should be noticed that
these investigations made a basis for creation
of new pegylated blood cells that would find
practical application especially in «transplant
against host» reactions [27].
Pegylated α?2b interferon. One more field
of future use of peptide structure pegylated
agents is antiviral therapy. Traditional regime
of αinterferon administration is 3 million IE
3 times a week. It is important to note that
peak interferon concentration is observed
within 8–12 hours after hypodermic injection;
its halflife period is 6 hours at average. It is
clear that together with stable concentration
periods there are periods when level of inter
feron in serum and biological tissues could
come down to the almost indeterminable val
ues. It is logically to assume that for reaching
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the acceptable therapeutic level of native exo
genic interferon (IFN), it is necessary to
change its pharmacodynamic and pharmacoki
netic parameters fundamentally. This require
ment caused creation of basically new pharma
ceutical form of α2b interferon in
conjugation with PEG. Pegylated IFN has
noticeably better biological profile than ordi
nary interferon; it appears in greatly
increased halflife period of pegylated analog
and in decreased immunogenic characteris
tics. Coupling of a relatively small PEG mole
cule of molecular weight 12 kD to interferon in
vivo showed that maximal protein concentra
tion is reached in 15–44 hours and remains
during 48–72 hours. Therefor effective half
life period makes up 40 hours in average.
Slowing down of PEG interferon clearance
from plasma provides its circulation in blood
during a week. Pharmacokinetic and pharma
codynamic parameters provide exactly really
high effectiveness of α2b PEG interferon in
comparison with a standard analog. Besides,
PEG molecular weight provides not only liver
but kidney clearance as well. One more impor
tant advantage of pegylated α2b interferon in
contrast with normal recombinant interferon
is ability to use it for cirrhosis treatment
because this group patients was usually
deprived of full antiviral therapy. So, the bal
ance between antiviral activity and long peri
od of partial ejection is typical for pegylated α
2b interferon; it allows to prescribe an agent
one time a week and to remove PEG metabo
lites from an organism effectively [19, 23, 28].
Receptor–dependent endocytosis
Depending on cell absorption mechanism
of the macromolecules and particles, endocy
tosis could be divided into constitutive (or liq
uidphase) and receptordependent one. In the
first case a nonselective process takes place
during which concentration of the substances
that are absorbed as a part of vesicles corre
sponds to a concentration of the substances in
the extracellular liquid. Receptor–dependent
endocytosis (figure 2) is exclusively selective
concentrating mechanism that enabled the
cells to absorb lots of specific ligands without
absorbing large volume of extracellular liquid
[29–32]. At the same time macromolecules
that have limited number of binding sites on
the plasmalemma are absorbed. These sites
have high affinity to the certain substances.
The sites absorb separately substances from
the cell space and concentrate them. In addi
tion the liquids and dissolved strange mole
cules that don’t bind with the receptors are
slightly absorbed. Thus effective flux of the
specific molecules into a cell is provided.
During endocytosis vesicles are formed in the
places of plasmalemma invagination; on the
part of cytoplasm plasmalemma is coated with
fibrous material — membranous protein clath
rin. The pits coated with clathrin that could
occupy up to 2% of some cells surface are
formed in advance. By means of these coated
pits where the corresponding receptors are
located a number of substances, such as low
density lipoproteins, growth factors, hor
mones etc. are internalized [1]. 
Use of protein vectors that are specific to
cell receptors. In developing of common use
anticancer agents, hybrid covalent bound con
jugates of «protein vector — chemoagent»
type method was widely used. Selectivity of
conjugates action is obtained due to presence
of the specific receptors on the tumor cells sur
face that are recognized by cargo protein or
antibody or due to a considerably higher
expression level of cargo protein receptors on
the tumor cells surface in comparison with the
normal cells. The data concerning successful
use of cytotoxic conjugates created on a basis
of cytotoxic antibiotics and cargo molecules
Fig. 2. Receptor>dependent endocytosis phases:
Ligand and receptor binding (1), coated pit forming
(2), Clathrin vesicle forming (3), intracellular utiliza
tion (4–6)
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delivering antibiotic directly into tumor cells
or tumor vessels endothelial cells are pub
lished in a number of works [33]. Oncofetal
proteins, transferrin, monoclonal antibodies
to specific tumor antigens, hormonelike pep
tides etc. are widely used as cargo molecules.
Conjugation of cargo protein and agent
could be carried out in several ways: by means
of chemical crosslinking (in a simple case it is
disulfide or thioester bridges), polyethylene
glycol or polypeptide linker, avidinbiotin
technology etc. Methods of bioconjugation are
described more detail in the work [34]. In any
case method of conjugation should satisfy two
main criterions: high reaction yield and abili
ty of intracellular breakdown. The last
requirement is unessential. In such a case vec
tor «independence» of an agent is determined
by sizeable length of a linker. For these linkers
creation usually PEG with molecular weight
up to 2–3 kD is used [35]. 
The cytotoxic antibiotics and apoptosis
inductors etc. are used as antitumor agents.
It is clear that specificity of conjugate
action is determined first of all by a structure
and type of cargo protein. 
Transferrin?transferrin receptor. It is well
known that ferrum (Fe3+) transport in an
organism takes place as a complex with globu
lin protein under transferrin (Trf). Ferrum
transport into a cell is a result of endocytosis
due to Trf interaction and its receptor (TRFR)
[36, 37]. Transferrin is widely used as a cargo
protein for directed delivery of the anticancer
agents, proteins and genes to a tumor cell for
which higher TRFR expression level is typical.
Tfrspecific intracellular delivery is achieved
by conjugation of this cargo protein with some
antitumor agents (doxorubicin, daunorubicin)
and protein toxins (СRM107, ricin) [38]. Use
of such constructions allows to decrease essen
tially toxicity of chemotherapy and to with
stand somehow cancer cells acquired resis
tance mechanisms. 
Hormones and their receptors. Peptide
hormones having specific receptors on their
cells surface also could be effectively used as
cargo molecules. Particularly it was deter
mined that variant carcinoma and prostate
overexpression in the tumor cells was observed
for decapeptide gonadoliberin receptors at car
cinogenesis of breast, ovarian carcinoma and
prostate [39, 40]. That’s why gonadoliberin
could be used for directed delivery of medical
agents to such kinds of malignant tumors.
Thus for conjugate consisting of gonadoli
berin, PEG and camptothecin high antitumor
activity on the mouses was shown. This con
struction was nontoxic and at the same time
increased gonadoliberin concentration showed
lack of considerable physiological effect on repro
ductive functions of the tested animals [39].
Insulin receptors, found almost in all
organism tissues, are of the utmost interest
for studying [41]. In particular, a lot of tumor
cells are characterized by a high level of insu
line receptors expression [42–45].
In a structure of every hormone the centers
that determine interaction of a hormone only
with the target cells could be marked [46].
Consequently, it seems possible to create a
liposomal vector based on a structure of that
site of insuline molecule that is charged for
interaction with a receptor. It is known from
the publications that an area on the Cterminal
ends of A and Bchains of an insuline mole
cule is responsible for binding and biological
activity manifestation [47].
In [48] it is described synthetic decapeptide
which aminoacid sequence is correlated with
19–26 aminoacid residues of Bchain and 20–21
aminoacid residues of Achain insuline mole
cule bonded against each other with a short
peptide. A short fragment which aminoacid
sequence corresponds to 23–26 aminoacid
residues of Bchain and 2021 aminoacid
residues of Achain insuline molecule inter
connected with a short peptide bond has been
created as well [48]. This fragment includes a
hydrophobic sector of Cterminus of insuline
molecule Bchain. This is the most important
sector that is responsible for combining with a
receptor and for dimeres formation [49]. Both
peptides were acylated on the Nterminus by
ether of palmitic acid. After they were built in
the lipid double layer. Acylated peptides
included into the liposomes could firmly bond
with insuline receptor of rat pheochromo
cytoma РС12 cells in vitro; further it resulted
in receptordependent liposomes endocytosis
[48]. 
Oncofetal proteins. Some oncofetal pro
teins, for example αfetoprotein (AFP), could
also be used as cargo molecules for the medical
agents delivery into the tumor cells.
Advantages of their use are absence of
immunogenic characteristics, high affinity to
the receptors and high level of receptors
expression on the tumor cells [50, 51]. It was
shown that AFP receptors were expressed on a
surface of the overwhelming majority of the
tumor cells while on the normal cells the recep
tors weren’t expressed or expressed in the
minor amounts [52].
The abovementioned experimental data
concerning an expression level of the AFP
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receptors and high endocytosis speed enabled
to make an assumption concerning high selec
tivity of delivery of conjugates of AFP with
cytotoxic agents into the tumor cells. 
Conjugates of AFP with different chemo
therapy agents (phthalocyanines, chlorines,
alkaloides and anthracyclines) were created
and studied. Research results have shown that
use of AFP as a cargo molecule made it possi
ble to increase cytotoxicity of the most me
dical agents studied concerning tumor cells
lines [52–59]. Conjugates of AFP with doxoru
bicine were characterized by high antitumor
activity and their cytotoxic activity concern
ing antibiotic resistant tumor cells was in
large excess over uncombined doxorubicine
activity [52–54]. Investigations on the mouse
solid tumors models have shown that AFP con
jugates with cytotoxic agents are upon pro
nounced inhibitory action on the tumors and
in comparison with uncombined antibiotics
they prolong notedly life time of the experi
mental animals [52, 53]. Positive results were
received as well when conjugates of epidermal
growth factor (EGF) and receptorbonding
EGF fragment were used with the antitumor
agents [56–63].
Another possible approach is creation of
the directed action agents in a form of AFP
conjugates with antisense oligonucleotides
(ASON) to mRNA genes that play a key role in
regulation of cell proliferation and apoptosis.
ASON using experiments for ingibition of
mRNA genes translation which hyperexpres
sion leads to transformation of normal cells to
tumor showed high ASON specifity to their
targets [64, 65]. Unlike most chemotherapy
agents, ASON are easily biodegraded and
egested from an organism. To avoid their
degradation by endonucleases and exonuclea
ses, modified oligonucleotides are used where
of the most perspective are phosphorothioate
derivates [2]. At the same time there is a num
ber of problems due to insufficient effectivity
of their delivering into the tumor cells. 
Monoclonal antibodies and immunolipo?
somes. Monoclonal antibodies (mAb) to differ
ent receptors on the cancer cells surface
(TRFR, epithelium growth factor receptor,
CDreceptors) are the most wideused cargo
molecules. Production of such mAbs underlies
an oncovaccine action. Moreover, the radiola
beled mAbs that are bond with a cell and cause
its death because of presence of radionuclides
in their structure are sometimes used. Besides
mAbs are often conjugated with cytotoxic
antibiotics and other bioactivity substances by
different linkers (avidin biotin, PEG, etc.)
[56]. Use of conjugates based on mAb to recep
tors is often more effective than use of natu
ral ligands as cargo molecules. For example,
Tfr is characterized by limited ability to per
meate through hematoencephalic barrier that
doesn’t make it possible to use Tfr in therapy
of brain oncological deseases. At the same time
antibodies to TRFR permeate freely to differ
ent brain tissues [67].
An original tendency in creation of directed
drug delivery systems is immunoliposomes —
liposomes with attached monoclonal antibo
dies [8]. Monoclonal antibodies provide speci
fic binding of liposomes with antigenpositive
cells while liposomes carry appropriate hydro
phobic or hydrophilic chemotherapy agent. 
Nowadays there are three types of immu
noliposomes: A, B and C [68]. mAbs of A type
immunoliposomes are covalently bound with
normal liposomes by a short linker. B type is
already PEG liposomes that is bound covalent
ly with mAb by a short linker. Type C
(Pendanttype PEGimmunoliposomes) is
steric stabilized PEGliposomes with mAb
attached to distal terminal PEG end.
By means of type A liposomes it was shown
that immunoliposomes were more effective in
delivering drugs to the target cells in compar
ison with normal liposomes both in vitro and in
vivo tests [69]. However immunoliposomes
binding with the target cells in vivo was more
complicated. Study of immunoliposomes in
vivo showed that antibodies attaching to lipo
somes strengthened their absorption by RES
mononuclear leukocytes. Effectivity of lipo
somes adhesion with the target cells depended
on antibodies thickness on the liposomes sur
face. Immunoliposomes absorbtion by RES
cells and endothelial barrier compelled the sci
entists to create a new type of liposomes. It
resulted in construction of steric stabilyzed
immunoliposomes with a prolonged period of
circulation in blood.
In the earliest works concerning longper
sistent immunoliposomes creation, the anti
bodies were bound by short hydrophilic linker
close to a surface of liposomes (type B); these
steric stabilized liposomes contained phospho
lipids with PEG modified main groups [70].
The liposomes kept ability of longcontinued
circulation but interaction with the target
cells was suppressed by PEG blockade [71].
Later mAb were attached to the distal ends
of PEG chains bound with type C liposomes. It
resulted in keeping the steric stabilized lipo
somes ability to bind specifically with a target
cells surface and to be protected from absorp
tion by RES mononuclears [72].
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Nowadays for the purpose of getting the
stable connection of antibodies with PEG,
three conjugation methods are used for cova
lent binding mAb and PEG terminal ends: by
thioether bond [73], by amid groups [68] and
by hydrazones [74].
It should mentioned that there are some
requirements to antibodies used in immunoli
posomes construction. They should keep their
specifity when conjugate with liposomes, have
enough affinity for low concentration lipo
somes binding and have low immunogenity.
For this purpose chimeric and humanizated
mAb and Fab antibodies fragments are used.
Antibodies should be intensively internalized
by the target cells through endocytosis, have
biological activity and intensify antitumor
response. Monoclonal antibodies should be man
ufacturable and have enough storage life [74].
There are some requirements to antigene
being a target for liposomes. It should be
strong and homogeneous at express in tumor
tissue and not disappear from a cell surface.
Antigene desquamation from a tumor cell
surace should be minimal to avoid immunoli
posomes and soluble antigene binding or clear
ance intensification. «Antigeneimmunolipo
some» complex should pinocytate into a tumor
cell. Bond between antigenes and liposomes
should be stable in blood. Linker shouldn’t
bind with a molecule site recognized by anti
gene, should be interimmunogenic, atoxic,
avoid opsonization, be inert towards a medical
agent inside liposome and liposome membrane
stability and not put steric obstacles.
Ratio of antibodies and lipides in immuno
liposome is an important factor [68]. Thus, at
1:50 weight proportion one liposome was
added to 24 mAb molecules while at 1:1 pro
portion — 935 antibodies were. Specific accu
mulation of immunoliposomes with 1:50 pro
portion was 3% of a given dose, and
accumulation of immunoliposomes with pro
portion 1:1 was 60% of a given dose. Immuno
liposomes absorption by the liver cells was
reduced from 50% of a given dose for the lipo
somes with low content of antibodies to 12%
for the liposomes with high content of anti
bodies. At that, absorption of liposomes con
taining small amount of antibodies didn’t dif
fer from normal liposomes absorption.
Liposomes that didn’t bind with the target
cells at the several first passages through
tumor capillaries were accumulated in liver
and spleen [68].
Specific delivery of antitumor agents by
means of immunoliposomes stimulated better
therapeutical effectiveness and reduce toxici
ty as compared with normal liposomes [75]. It
was clearly demonstrated on the mouse solid
tumor models [76] and on the nude mice het
erologous grafts of human Bcell [73].
By now several immunoliposome prepara
tions perspective for use in oncological prac
tice has been described. They are directed
against the cells that express the following
antigenes: CD71 (transferrin receptor),
Her2/neu (epidermal growth factor receptor)
[77], HLADR (MHC II antigenes) [78, 79],
CD19 (Bcells marker) [73], LL2 (Bcells lym
phoma antigene) [80].
Cell penetrating peptides. Until quite
recently use of polypeptides and oligonu
cleotides for research and therapeutical pur
poses was restricted because of their low
permeability through biomembranes and rela
tively quick degradation inside a cell. This
restriction was an obstacle for biomedical
researches and also for pharmaceutical indus
try. Hydrophilic macromolecules transport
into cytoplasm and nucleus bioplast seemed to
be impossible without membranes destruction.
At the same time delivery of biologically
active macromolecules inside a cell open wide
prospects for the biological objects manipula
tion. That’s why discovery of peptides that are
able to permeate into a cell without membrane
proteins assistance and put intracellular
transport in force of protein fragments and
oligonucleotides bound with them opens a new
phase in development of biology and medicine.
Such peptides are called «сell penetrating pep
tide» (CPP). Sometime such type of peptides is
called «Troic horse» as well [8183]. 
CPP is isolated from proteins of different
organisms from viruses (HIV1, herpes,
influenza) up to vertebrates (cayman). Typical
and most studied CPP is penetratine (pANTP).
It is 16 aminoacids peptide isolated from
Antennapedia Drosofila melanogaster protein
[81]. TAT peptide is a fragment of immunode
ficiency virus HIV1 capside protein [82, 83],
and VP22 peptide is a fragment of herpes sim
plex virus capside protein [84].
According to physicalchemical character
istics CPP could be divided into two groups:
hydrophobic (FGF of Kaposi’s sarcoma glyco
protein, gp41 of HIV1 glycoprotein and Ig(v)
of cayman immunoglobuline light chain) and
amphiphile (Hel 117 of influenza viruse
hemagglutinin, TAT, VP22 and pANTP).
Length of such peptides varies from 11 to 30
aminoacids. Analysis of CPP aminoacid
sequence didn’t find homology between them,
but it was noticed that almost always there are
several arginine molecules. Investigation of
БІОТЕХНОЛОГІЯ, Т. 2, №1, 2009
54
such regularity enabled some researchers to
consider internalization as a property of argi
ninerich peptides. However later on amino
acid sequences that don’t contain arginine and
are in a position to permeate through cyto
plasm membranes have been synthesized [85].
Mechanism of CPP transport through a cell
membrane is unknown at the present. But it is
known that transport takes place without
membrane proteins assistance, it practically
doesn’t depend on carbohydrates expression
character and is energy independent [86].
Some сell penetrating peptides (ТАТ, VP22)
are able to permeate through intracellular
membranes and accumulate into the cell nucle
us. It is experimentally proved that CPP pene
trate in different cell types with equal effec
tiveness and even could overcome a mammal’s
histohematogenous barrier [87].
It was shown that these peptides could
transport aminoacid and oligonucleotide
sequences covalently bound with them
through a cell membrane. These sequences
have molecular weight up to several kD and
resist intracellular hydrolysis for a long time
because they are located out of lizosomal
enzymes effective area. Thus, сell penetrating
peptides could act as transport mechanism of
physiologically active macromolecules parts
into a cytoplasm or even into a cell nucleus
[88]. Such unique CPP characteristics enabled
to create directly the chimeric molecules con
sisting of сell penetrating peptide and
a macromolecule fragment covalently boun
ded with it [87, 88].
Modern literature review concerning
approaches to creation of the purposeful drug
delivery systems of anticarcinogenic vaccine
preparations and genotherapy agents are made
in the article. Targeted drugs delivery is
implemented by use of liposomal forms and
receptordependent endocytosis. The main
problem of liposomal preparations is bad phar
macokinetic indices conditioned by liposomes
instability, their quick opsinization at intra
venous administration and further absorption
by RES cells. This problem is mainly solved by
means of covalent binding with polyethylene
glycol that gives hydrophile characterictics to
liposomes. Receptordependent endocytosis is
used for specific drug delivery to the target
cells . The transferrin, hormones (for example
gonadoliberin and insulin), oncofetal proteins
(such as αfetoprotein and epidermal growth
factor), monoclonal antibodies and peptides
able to permeate inside the cell are used as pro
tein vectors.
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В огляді узагальнено дані літератури щодо
підходів до створення систем цілеспрямова
ного доставлення лікарських засобів, які базу
ються на використанні ліпосомальних форм та
рецепторопосередкованого ендоцитозу. Розг
лянуто підходи до використання систем спря
мованого доставлення при створенні антикан
церогенних, антибактеріальних препаратів,
вакцин, а також у генотерапії. 
Ключові слова: системи цілеспрямованого достав
лення, лікарські засоби, ліпосоми, ендоцитоз, про
тиракові препарати, моноклональні антитіла.
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В обзоре обобщены данные литературы отно
сительно подходов к созданию систем целена
правленной доставки лекарственных средств,
основанных на использовании липосомальных
форм и рецепторопосредованного эндоцитоза.
Рассмотрены подходы к использованию сис
тем направленной доставки при создании ан
тиканцерогенных, антибактериальных препа
ратов, вакцин, а также в генотерапии. 
Ключевые слова: системы целенаправленной дос
тавки, лекарственные средства, липосомы, эндоци
тоз, противораковые препараты, моноклональные
антитела.
